ClinicalTrials.gg
Status unknownNCT03790384MITOBCGUpdated Dec 31, 2018

Sequential Combination Therapy in Bladder Cancer

A Phase 4 interventional study of Mitomycin in Bladder Cancer, sponsored by Azienda Ospedaliera "Sant'Andrea". Status unknown. Open to male participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-31.

Sponsored by Azienda Ospedaliera "Sant'Andrea" · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Dec 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
30 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing mitomycin in Urinary Bladder Neoplasms — 5 open to participants now, 10 under way, 2 of them phase 3. Mitomycin · Urinary Bladder Neoplasms.

Planned enrollment
5th of 26
140 · median 61
Started
2019
the only one that year
Phase 4
2 of 26
none open now
Registered
15th of 26
by date
Lead sponsor
1 of 26
Azienda Ospedaliera "Sant'Andrea"

Among the 26 studies testing mitomycin in Urinary Bladder Neoplasms, this one is the 5th largest by planned enrollment, is the only one that started in 2019, is one of 2 in phase 4, and was the 15th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

5 of the 26 studies testing mitomycin in Urinary Bladder Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About mitomycin

Mitomycin: first FDA approval 1981 (MUTAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 30 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing mitomycin in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

A consecutive series of patients with High Risk Non-Muscle Invasive Bladder Cancer will be enrolled in several centres. The subjects will be assessed for eligibility at the screening visit (Visit 1) three weeks after Trans-Urethral Resection of the Bladder (TURB) and re-TURB prior to randomization and only subjects who fulfil the inclusion criteria will be included. Patients selected for the study, are centrally randomized (randomization is performed at the Sant'Andrea Hospital) to receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with Immucyst (81 mg Connaught strain BCG). Patients in group two received BCG treatment with the same protocol with a 40 mg mitomycin instillation the day before .

Read the detailed description

Methods:

A consecutive series of patients with High Risk Non-Muscle Invasive Bladder Cancer will be enrolled in several centres

Clinical evaluation:

Patients with High Risk Non-Muscle Invasive Bladder Cancer will be enrolled. For each patients we evaluate the following parameters:

  • Age
  • Sex
  • Occupational status
  • Smoker Status
  • Co-morbidities
  • Concomitant medications or treatment
  • Height, Weight, BMI
  • Urinary symptoms evaluation:

    • Presence of Haematuria at the diagnosis
    • International Prostatic Symptoms Score
  • Laboratories Analyses

    • Hemoglobin serum level
    • Creatinine
  • EORTC/EAU risk stratification
  • Endoscopic bladder evaluation (video-recorded and centrally evaluated)

    • Number of Tumors
    • Diameter of Tumors (\<3 cm or > 3 cm)
    • Location of Bladder Tumors
  • TURB (video recorded) + histological examination
  • Re-TURB showing no evidence of neoplasms
  • Follow-up

    • Cystoscopy (video will be recorded and centrally re-evaluated for recurrence) and cytology every three months later
    • Recurrence Rate
    • Number of Recurrence Rate
    • Number of Tumors
    • Diameter of Tumors
    • Location of Bladder Tumors
    • Urethral Stricture
    • Bladder mapping at 6 months
    • Uro Tomography Computerized yearly

Intervention:

The subjects will be assessed for eligibility at the screening visit (Visit 1) three weeks after TURB and re-TURB prior to randomization and only subjects who fulfil the inclusion criteria will be included: patients with a diagnosis of High risk Non Muscle Invasive Bladder Cancer (NMIBC): T1 tumor, G3, Carcinoma in Situ (CIS), or multiple and recurrent and large (>3 cm) Ta or patients in the last EAU recurrence category (EAU/EORTC recurrence score >/=10). Patients selected for the study, are centrally randomized (randomization is performed at the Sant'Andrea Hospital) to receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with Immucyst (81 mg Connaught strain BCG). Patients in group two received BCG treatment with the same protocol with a 40 mg mitomycin instillation the day before .

Adverse Events All the adverse events that will occur in the study will be recorded in the case report form (CRF).

An adverse event (AE) is defined as a harmful clinical event occurring in a patient or a human volunteer involved in a clinical experimentation who received a drug that does not necessarily have a relationship with the treatment given. It is considered AE any medical occurrence including undesirable signs or symptoms or abnormal lab finding.

A Serious Adverse Event (SAE) is an AE that, independently from the dosage of the drug used, had one of the following characteristic:

  1. Results in death
  2. It's life threatening (i.e. the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe)
  3. It's cause of hospital admission or increase the time of hospitalization
  4. It's cause of congenital abnormalities at birth
  5. It's cause of disability or severe and long lasting inability Treatment Emergent Adverse Events (TEAE) is defined as any event not present prior to the initiation of the treatments or any event already present that worsens in the either intensity or frequency following exposure to the treatments.

A Suspected Unexpected Serious Adverse Reaction (SUSAR) is the term used to refer to an adverse event that occurs in a clinical trial subject, which is assessed as being unexpected, serious and as having a reasonable possibility of a causal relationship with the study drug. It is defined as an untoward and unintended response to a study drug, at any dose, which is not listed in the product information, and meets one of the above mentioned serious characteristics.

Generally AEs are collected after signing the informed consent form and could be related or unrelated to the study drug.

For any AE/SAE recorded during the study a causal relationship with the drug used will be assessed as follows:

  • Very likely: the AE/SAE is temporally associated to the drug administration, cannot be explained by other clinical conditions and/or concomitant treatments, disappears with drug withdrawal and recurs after drug reintroduction;
  • Likely: the AE/SAE is temporally associated to the drug administration, cannot be explained by other clinical conditions and/or concomitant treatments, disappears with the drug withdrawal. There is no information on drug reintroduction;
  • Possible: the AE/SAE is temporally associated to the drug administration, cannot be explained by other clinical conditions and/or concomitant treatments, disappears with drug. There is no information available on the drug withdrawal and reintroduction;
  • Doubtful: the AE/SAE could be temporally associated to the drug administration, but can be explained by other clinical conditions and/or concomitant treatments;
  • Not correlated: the AE/SAE is not temporally associated to the drug administration and/or can be explained by other clinical conditions and/or concomitant treatments.
  • An AE/SAE with causal relationship very likely, likely possible with the drug is considered correlated with it and is defined Adverse Reaction (ADR).

World Health Organization (WHO) defines ADR as "a response to a drug which is noxious \& unintended and which occurs at doses normally used for prophylaxis diagnosis or therapy of a disease or for modification of a physiological function".

The difference between AE and ADR is that AE event does not imply causality but not for ADR, a causal rule is suspected.

An ADR unexpected is defined an ADR that for nature and severity is not listed in the product information (Reference Safety Information (RSI)/Investigator's Brochure (IB)).

Toxicity evaluation Urine culture is performed 3 days before each bladder instillation to check urine sterility (mandatory before the first course, optional before the following instillations). Treatment related adverse events are recorded by the patients on a diary.

Outcome analysis: adverse events are self-recorded by the patients after each instillation and classified by the investigator according to a classification grid considering account duration and intensity as proposed by Saint et al. Thus, toxicity is classified as systemic or local and class I (mild) up to class III (severe). The baseline symptoms are also assessed. Local toxicity included bacterial cystitis, BCG induced cystitis, frequency, macroscopic hematuria and "other". Bacterial cystitis is defined as the occurrence of culture proven (not BCG) bacterial cystitis. Irritative bladder symptoms with negative urine culture are classified as BCG induced (chemical) cystitis. "Other" local side effects include granulomatous prostatitis, epididymitis, ureteral obstruction and contracted bladder. Systemic side effects are classified as fever (≥39 °C), influenza like symptoms including general malaise and chills, BCG induced lung infection, liver toxicity, and BCG sepsis. Skin rash, arthralgia and arthritis are classified as possible allergic reactions. Based on the severity of adverse events experienced by the patient, one of the investigator, who is blind to the given therapy, decides whether the next instillation is to be done, postponed, deleted or whether the patient should receive specific anti-tuberculosis therapy. Dose reduction is not allowed in either group. Patients will also complete flow-volume charts for three days after BCG instillations and two questionaries to assess urinary symptoms and patient's perception of bladder pain as the chronic prostatitis symptoms index (NIH-CPSI) and the pelvic pain and urgency/frequency questionaire (PUF). The efficacy of both treatments is assessed at 3, 6,9,12 months with flexible cystoscopy, urinary cytology and bladder biopsy if needed.

STATISTYCAL ANALYSIS Using type I error, and a power of 2.5% and 81% respectively, and by proposing the hypothesis that Immucyst induced a recurrence in about 60% of cases (EORTC risk score 10) and its combination with mitomycin decreases this percent by 30%, it was calculated that 66 subjects per group were necessary to detect this difference using the adjusted chi-square method and Statistical Solution calculator. Student's T test was used for continuous variables. Two-sided p values were calculated.

03

Conditions studied

  • Bladder Cancer
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with high risk non muscle invasive bladder cancer
  • High risk of progression (EORTC risk score > 6)
  • Males
  • Signature of
  • Ability of consent

Exclusion criteria

Exclusion Criteria:

  • Low Risk Non-Muscle Invasive Bladder Cancer
  • Muscle Invasive Bladder Cancer
  • Concomitant Urothelial Bladder Cancer in the Upper-Urinary Tract
  • Previous bladder or prostate surgery
  • Prostate or bladder radiotherapy
  • Urinary tract infection
  • Chronic urinary retention or indwelling catheters
  • Neurological patients
  • Previous BCG infections
  • Previous or current chemotherapy for other kind of cancers
  • Patients older than 75
  • 3-4
  • Residual tumour on re-TURB
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
140 participants (estimated)

Study arms

  • No intervention
    Bacillus Calmette-Guérin

    Patients receive Bacillus Calmette-Guérin induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG).

  • Experimental
    Mytomicin and Bacillus Calmette-Guérin

    Patients received BCG treatment with the same protocol. Intervention will be a 40 mg mitomycin instillation the day before every single BCG instillation

    Drug: Mitomycin

Interventions

  • Patients receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG) with a 40 mg mitomycin instillation the day before .

    Also known as: Bacillus Calmette-Guerin

06

What researchers measure

Primary outcomes

  1. Recurrence rate

    To evaluate the effect in term of recurrence rate of sequential combination therapy of Mitomycin and Bacillus Calmette-Guérin versus Bacillus Calmette-Guérin monotherapy in patients with High grade Non-Muscle Invasive Bladder Cancer.through cystoscopy every three months and Uro Tomography Computerized yearly

    Time frame: 2 years

Secondary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    To evaluate the overall toxicity of sequential combination therapy of Mitomycin and Bacillus Calmette-Guérin versus Bacillus Calmette-Guérin monotherapy through CTCAE v4.0. Patients have to fill in International Prostate Symptoms Score, NIH-CPSI, PUF questionaries. Every three months patients will be visited and have a cystoscopy. We will hear about self-reported symptoms and we will measure body temperature

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Solsona E, Madero R, Chantada V, Fernandez JM, Zabala JA, Portillo JA, Alonso JM, Astobieta A, Unda M, Martinez-Pineiro L, Rabadan M, Ojea A, Rodriguez-Molina J, Beardo P, Muntanola P, Gomez M, Montesinos M, Martinez Pineiro JA; Members of Club Urologico Espanol de Tratamiento Oncologico. Sequential combination of mitomycin C plus bacillus Calmette-Guerin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur Urol. 2015 Mar;67(3):508-16. doi: 10.1016/j.eururo.2014.09.026. Epub 2014 Oct 6. PubMed 25301758 ↗
  • Cui J, Wang W, Chen S, Chen P, Yang Y, Guo Y, Zhu Y, Chen F, Shi B. Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis. Medicine (Baltimore). 2016 Jan;95(3):e2572. doi: 10.1097/MD.0000000000002572. PubMed 26817914 ↗
  • Kaasinen E, Wijkstrom H, Rintala E, Mestad O, Jahnson S, Malmstrom PU. Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. Scand J Urol. 2016 Oct;50(5):360-8. doi: 10.1080/21681805.2016.1210672. Epub 2016 Aug 15. PubMed 27603424 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2019; primary completion for Sep 2019, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2018
First posted
Dec 31, 2018
StartEst.
Jan 15, 2019
Primary completionEst.
Sep 15, 2019
CompletionEst.
Jan 15, 2021
Last update
Dec 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03790384
Lead sponsor
Azienda Ospedaliera "Sant'Andrea"
Responsible party
Sponsor
First posted
Dec 31, 2018
Start date
Jan 15, 2019 (estimated)
Primary completion
Sep 15, 2019 (estimated)
Completion
Jan 15, 2021 (estimated)
Last update
Dec 31, 2018

Study contacts

Andrea Tubaro
Contact
andrea.tubaro@mac.com
+390633777712
Andrea Tubaro
principal investigator · Azienda Ospedaliera "Sant'Andrea"

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitomycin

Start the discussion